Arcellx is developing a cell therapy called anitocabtagene autoleucel (anito-cel) that could be a safer alternative to current CAR T-treatments for multiple myeloma. Preliminary data show no neurological complications associated with other therapies in its class. In a Phase 2 study, 97% of patients responded to anito-cel with 62% achieving a complete response. Anito-cel’s safety profile is a key selling point, as it has shown no cases of parkinsonism, nerve damage, or other serious side effects. Gilead Sciences partnered with Arcellx on anito-cel, investing $225 million upfront with potential milestone payments of up to $3.9 billion. Manufacturing turnaround time for anito-cel is 17 days, shorter than the industry standard, and the therapy has a high success rate in production. Analysts believe anito-cel has best-in-class potential due to its safety and manufacturing advantages.
Source link
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages
